Follicular Lymphoma News and Research

RSS

Follicular lymphoma is one of the most common kinds of non-Hodgkin lymphoma. Its progression rate varies widely, though it tends to spread slowly and has few symptoms. Patients with follicular lymphoma usually survive ten years or longer.

Gene Splicing Affects CD20 Expression and Response to Cancer Immunotherapy

Gene Splicing Affects CD20 Expression and Response to Cancer Immunotherapy

Immunotherapies that target the CD20 antigen have revolutionized how patients with a variety of blood cancers and hematologic disorders have been treated.

17 Nov 2023

High-risk lymphoma patients may receive durable benefit from axi-cel CAR T cell therapy

High-risk lymphoma patients may receive durable benefit from axi-cel CAR T cell therapy

Three clinical studies led by researchers at The University of Texas MD Anderson Cancer Center demonstrated enhanced responses for patients with high-risk lymphoma treated with axicabtagene ciloleucel (axi-cel) chimeric antigen receptor (CAR) T cell therapy.

13 Dec 2021

CAR T-cell therapy reduced cancer cells in patients with advanced non-Hodgkin lymphoma

CAR T-cell therapy reduced cancer cells in patients with advanced non-Hodgkin lymphoma

A CAR T-cell therapy known as axicabtagene ciloleucel (axi-cel) drove cancer cells to undetectable levels in nearly 80% of patients with advanced non-Hodgkin lymphoma (NHL) in a phase 2 clinical trial, Dana-Farber Cancer Institute investigators report at the virtual 62nd American Society of Hematology (ASH) Annual Meeting.

7 Dec 2020

New approach is more effective in treating certain blood cancers

New approach is more effective in treating certain blood cancers

Some of the most promising advances in cancer treatment have centered on immunotherapies that rev up a patient's immune system to attack cancer.

24 Jul 2020

Hi, I'm Azthena, you can trust me to find commercial scientific answers from AZoNetwork.com.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.